Emplicure AB (publ) has today entered into a loan agreement with a loan consortium through which the Company has taken up a loan in the amount of 9.0 MSEK. The loan consortium includes certain existing shareholders, including the board member Johan Wieslander. The purpose of the loan is to strengthen the Company's short-term working capital and to meet the requirement of going concern for the next twelve months.

Emplicure AB announces today that the Nomination Committee for the annual general shareholders meeting (AGM) in May 2023 is formed. The Nomination Committee  consists of representatives nominated by the three largest shareholders per the last bank-day in the third quarter, as well as the Chairman of the Board. Emplicure's three largest shareholders, also the founders, have agreed to vote as one, in order to give preference for more shareholders.

Emplicure AB today reported dosing in the first Phase I pharmacokinetic study for EMPLI03, intended for the treatment of moderate to severe pain

Uppsala, 2022-10-03 Emplicure AB (publ) today announced that the company changes Certified Adviser

Uppsala 2022-09-19 Emplicure AB (publ) announces today that the Company's Board of Directors has resolved to implement a holding company structure with operational subsidiaries. The purpose of the restructuring is to increase visibility and reinforce the Group's ability to focus on business and product development across various product areas, including nicotine and pharmaceuticals as well as other consumer product areas. As a direct consequence of the above, the Board of Directors has appointed Tomas Hammargren as CEO of the subsidiary Amplicon.

Uppsala 2022-09-19 Emplicure AB (publ) announces today that the Company's Board of Directors has resolved to appoint member of the board and co-founder Håkan Engqvist as new CEO and President. 

The UK authorities have approved Emplicure's application to conduct a clinical pharmacokinetic study of Empli03, a drug candidate for chronic pain.

There is great interest in our unique patented bioceramic technology, which provides the opportunity to develop the next generation of nicotine pouches.

Amplicon, a wholly owned subsidiary of Emplicure AB that focuses on developing consumer products, successfully showcased two dry white nicotine-pouch products at the Global Forum on Nicotine in Warsaw on 16-18 June 2022.